Cargando…

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant

Fosaprepitant is a prodrug of aprepitant, a neurokinin(1) (NK(1)) receptor antagonist used in prophylactic antiemetic regimens used prior to cytotoxic chemotherapy. Fosaprepitant is being developed to provide a parenterally administered alternative to the orally administered aprepitant. Fosaprepitan...

Descripción completa

Detalles Bibliográficos
Autor principal:	Olver, Ian N
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504061/ https://www.ncbi.nlm.nih.gov/pubmed/18728837

Ejemplares similares

Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010)

Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives
por: Candelario, Nellowe, et al.
Publicado: (2016)

Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
por: Celio, Luigi, et al.
Publicado: (2013)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
por: Ando, Yosuke, et al.
Publicado: (2015)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects
por: Shimamoto, Fukutaro, et al.
Publicado: (2021)

Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
por: Hata, Akito, et al.
Publicado: (2022)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)
por: Weinstein, C., et al.
Publicado: (2016)

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
por: Zhou, Michelle, et al.
Publicado: (2015)

Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
por: Gyawali, Bishal, et al.
Publicado: (2016)

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
por: Willier, Semjon, et al.
Publicado: (2019)

Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial
por: Yang, Qi, et al.
Publicado: (2023)

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double‐blind, phase III study
por: Yang, L.Q., et al.
Publicado: (2017)

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
por: Bajetta, Emilio, et al.
Publicado: (2009)

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009)

The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Neurosurgery Patients: A Prospective, Randomized, Double-Blinded Study
por: Tsutsumi, Yasuo M., et al.
Publicado: (2014)

A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis
por: Murakami, Chiaki, et al.
Publicado: (2017)

Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015)

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)
por: Hata, Akito, et al.
Publicado: (2022)

Management of Patients With Chemotherapy-Induced Nausea and Vomiting
por: Barbour, Sally Yowell
Publicado: (2017)

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
por: Zhang, Zhonghan, et al.
Publicado: (2020)

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
por: Navari, Rudolph M, et al.
Publicado: (2023)

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007)

The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy
por: Lete, Iñaki, et al.
Publicado: (2016)

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
por: Saito, H., et al.
Publicado: (2013)

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics
por: May, Megan Brafford, et al.
Publicado: (2016)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
por: Weinstein, Cindy, et al.
Publicado: (2020)

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
por: Tan, Lijun, et al.
Publicado: (2009)

Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting
por: Bhandari, Prasan R.
Publicado: (2012)

Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
por: Navari, Rudolph M.
Publicado: (2015)

Management of postoperative nausea and vomiting: focus on palonosetron
por: Muchatuta, Neil A, et al.
Publicado: (2009)

A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
por: Matsumoto, Koji, et al.
Publicado: (2020)

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review
por: Tuca, Albert
Publicado: (2009)

Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective
por: Abe, Masakazu, et al.
Publicado: (2023)

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting
por: Ware1, Mark A, et al.
Publicado: (2008)

Chemotherapy-Induced Nausea and Vomiting: Updates and Recommendations
por: Viale, Pamela Hallquist
Publicado: (2018)

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting
por: Wang, Xiao-fei, et al.
Publicado: (2014)

Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain
por: Escobar Álvarez, Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ba5r52pf91vcc2tc8r60bb629